The inhibition of CyPA has been suggested to attenuate myocardial fibrosis [74], liver fibrosis [75], and pulmonary arterial hypertension [76], indicating that CyPA can promote the occurrence of these diseases. The gene discussed is PPIA; the disease is pulmonary arterial hypertension.